Biodexa Pharmaceuticals Plc
BDRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$3.43
KIRA · Stoqly’s AI analyst, in plain words
- Biodexa Pharmaceuticals Plc had only $0.1M of revenue in fiscal 2025: it is still developing what it sells. It spent $5.2M on research and development, 45% of its operating costs.
- Its operating margin was −10,803.0%, down 580.6 pts: of every 100 in sales, about −10,803 is left after running the business.
- Biodexa Pharmaceuticals Plc lost $8.4M in fiscal 2025. With no meaningful sales yet, it pays for its work from the cash it holds.
- Free cash flow was −$7.4M in fiscal 2025, −6,989.2% of revenue. At that burn of $7.4M a year, its $11.5M of cash and short-term investments would last about 1.6 years.
- Biodexa Pharmaceuticals Plc has $11.4M more cash than debt.
Market cap
—
P/E
—
Revenue
$0.1M
Net income
−$8.4M
Free cash flow
−$7.4M
Operating margin
−10,803.0%
Biodexa Pharmaceuticals Plc in 30 seconds · fiscal 2025
Are shareholders being diluted?
+1,007.7%
A lot. The share count rose 1,007.7% last year, so each share owns noticeably less.
Does it make a profit?
$5.2M R&D
Not yet: it has no meaningful sales. It spent $5.2M on research and development, 45% of its operating costs.
How long would its cash last?
1.6 yrs
For now. It burns $7.4M a year and holds $11.5M, about 1.6 years at that pace.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
4 / 8
It passes 4 of 8 health tests, but most of them need sales, so the score says little before revenue starts.
What Biodexa Pharmaceuticals Plc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 27, 2026
- Legal name
- Biodexa Pharmaceuticals Plc
- CIK
- 0001643918
Biodexa Pharmaceuticals Plc · BDRX · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.8M | $0.9M | $0.5M | $0.1M | $0.1M |
| Revenue growth | 80.8% | 8.3% | −45.0% | −75.7% | −8.3% |
| Operating margin | −1,210.8% | −1,277.8% | −2,103.3% | −10,222.4% | −10,803.0% |
| Net income | −$7.5M | −$9.4M | −$8.8M | −$7.3M | −$8.4M |
| Net margin | −944.7% | −1,095.3% | −1,857.9% | −6,366.3% | −7,977.7% |
| Diluted EPS | — | −$1.91 | −$0.02 | −$0.00 | −$0.00 |
| Cash | |||||
| Cash from operations | −$8.3M | −$8.7M | −$8.5M | −$15.7M | −$7.4M |
| Capital expenditure | $0.4M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$8.7M | −$8.8M | −$8.5M | −$15.7M | −$7.4M |
| FCF margin | −1,094.9% | −1,017.2% | −1,798.3% | −13,635.1% | −6,989.2% |
| Share count change | 88.0% | 22.7% | 6,291.4% | 1,468.1% | 1,007.7% |
| Debt and strength | |||||
| Cash and short-term investments | $13.6M | $3.4M | $7.6M | $2.1M | $11.5M |
| Debt incl. finance leases | $0.2M | $0.2M | $0.2M | $0.8M | $0.1M |
| Shareholders' equity | $14.1M | $3.8M | $5.9M | $10.4M | $15.4M |
| Current ratio | 6.4x | 2.5x | 1.3x | 1.8x | 2.0x |
| Interest coverage | −159.1x | −168.5x | −195.4x | −55.7x | −37.8x |
| Returns and quality | |||||
| Return on capital | −1,043.0% | −1,484.4% | — | −102.1% | −227.8% |
| Return on equity | −64.6% | −105.4% | −180.5% | −89.4% | −65.2% |
| Return on tangible equity | −53.3% | −248.0% | −148.0% | −70.2% | −54.8% |
| Piotroski F-score | 4 | 2 | 3 | 2 | 4 |
| Altman Z'' | −26.5 | −86.3 | −48.0 | −34.4 | −27.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Biodexa Pharmaceuticals Plc · BDRX · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.43 a share, the company is worth —.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001643918). Latest version: stoqly.net/companies/bdrx. Data updated November 1, 2026. Filed in GBP under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.